ClinicalTrials.gg
RecruitingNCT07803965Updated Oct 13, 2026

Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy

A Phase 2 interventional study of SGC001 injection and Placebo in Acute Pancreatitis, sponsored by Beijing Sungen Biomedical Technology Co., Ltd. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Beijing Sungen Biomedical Technology Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Pancreatitis with a site in China — 40 open to participants now, 44 under way, 2 of them phase 3. Pancreatitis · China.

Planned enrollment
35th of 75
129 · median 110
Started
2026
with 10 others
Phase 2
6 of 104
3 open now
Primary completion
2027-11
later than 32 of 43 live
Registered
103rd of 104
by date

Among the 104 studies in Pancreatitis with a site in China, this one is the 35th largest by planned enrollment of the 75 interventional ones that give a count, is one of 11 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 32 of the 43 other live ones, and was the 103rd registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

40 of the 104 studies in Pancreatitis with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Pancreatitis with a site in China, or all of them as a file.
02

Study summary

This is an early phase clinical study. Patients who are at high risk of developing severe acute pancreatitis will be screened. Participants will be randomly assigned to receive either SGC001 injection or a placebo injection that contains no active medicine. The study will check how safe and well tolerated SGC001 is, how the body processes this study drug, its biological effects, and whether it may help treat this condition.

The study consists of Part A, a dose escalation phase primarily focused on safety and tolerability, and Part B, a dose exploration phase primarily focused on efficacy, both administered as a single add on dose to standard care in patients with predicted severe acute pancreatitis.

03

Conditions studied

  • Acute Pancreatitis

Browse trials for

Keywords

  • SGC001
  • Predicted Severe Acute Pancreatitis
  • Acute Pancreatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75 years inclusive, with no restriction on gender
  2. Meet the diagnostic criteria for acute pancreatitis (AP) specified in the IAP Guidelines for the Management of Acute Pancreatitis (2025 Revision), i.e., satisfying at least two of the following three criteria: Clinical criterion: Acute epigastric abdominal pain; Biochemical criterion: Elevated pancreatic enzymes (serum lipase or amylase level more than 3 times the (ULN)); Imaging criterion: Abdominal imaging examination (computed tomography (CT) or ultrasound) demonstrating findings consistent with acute pancreatic inflammation, with or without necrosis.
  3. Meet the manifestations of predicted severe acute pancreatitis (AP)

Exclusion criteria

Exclusion Criteria:

  1. The exact onset time of abdominal pain cannot be accurately determined.
  2. History of endoscopic retrograde cholangiopancreatography (ERCP) performed within 7 days prior to screening;
  3. Received extracorporeal membrane oxygenation (ECMO) or renal replacement therapy prior to admission;
  4. Requirement for emergency surgery, ERCP, ECMO, renal replacement therapy or plasma exchange immediately upon admission;
  5. Having a known medical history of severe cardiovascular, respiratory, renal, hepatic, hematological or immune diseases;
  6. Subjects with current or a prior history of malignant tumors, except for basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder tumors or carcinoma in situ of the cervix that have been cured for at least 5 years.
  7. Subjects suffering from severe psychiatric disorders, cognitive impairment caused by severe social environmental factors, or any other conditions that the investigator judges may lead to poor protocol compliance or expose the subject to additional safety risks during the trial.
  8. Administration of within 1 month prior to screening;
  9. Female subjects who are pregnant or breastfeeding; female subjects of who have had unprotected sexual intercourse within 1 month prior to screening, or with a positive pregnancy test at screening; subjects (or their partners) who plan to conceive, donate sperm or oocytes throughout the study period and within 6 months after study completion; subjects who refuse to use one or more effective methods during the study and for 6 months following the end of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
129 participants (estimated)

Study arms

  • Experimental
    SGC001 Injection

    Drug: SGC001 injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Specification:400mg (10mL) per vial Part A: Dosage and Administration:300mg or 600mg, other dosage determined by the safety review committee (SRC) administered as a single intravenous infusion Infusion Duration:60±10minutes Part B: Based on clinical pharmacokinetic, safety and/or efficacy data obtained from the Part A dose escalation phase, the SRC will select 1 or 2 optimal dose cohorts. Infusion Duration:60±10minutes administered as a single intravenous infusion

  • DrugPlacebo

    Specification: 0mg(10mL)per vial Dosage Administration: 0mg as a single intravenous infusion Infusion Duration:60±10minutes

06

What researchers measure

Primary outcomes

  1. Part A: Safety Adverse Event (AE)

    Part A of this trial mainly analyzes on treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs), including clinically significant changes in vital signs, physical examination, electrocardiogram, and clinical laboratory tests, as graded by NCI CTCAE V6.0.

    Time frame: Part A Safety: Day 0- Day 85

  2. Part B: Days alive free of organ failure within 14 days post-randomization

    Time frame: Part B: Day 1-Day 15

Secondary outcomes

  1. Part B: Days alive without SIRS within 7 days and 14 days after randomization

    Time frame: Part B: Day 1-Day 15

07

Study locations

1 of 15 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2027, 14 months after the start.

Of 22 phase 2 interventional studies under Pancreatitis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 110. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 4, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Jan 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
15 sites changed recruiting status (14 now not yet recruiting, 1 now recruiting)
Show 15 sites
  • West China Hospital, Sichuan University · Chengdu, Chinano status→Not yet recruiting
  • The Affiliated Hospital of Guizhou Medical University · Guizhou, Chinano status→Not yet recruiting
  • Zhejiang Provincial People's Hospital · Hangzhou, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Nanchang University · Nanchang, Chinano status→Not yet recruiting
  • General Hospital of the Eastern Theater Command of the Chinese People's Liberation Army · Nanjing, Chinano status→Recruiting
  • Li Huili Hospital, Ningbo Medical Center · Ningbo, Chinano status→Not yet recruiting
  • Shanghai General Hospital · Shanghai, Chinano status→Not yet recruiting
  • General Hospital of Northern Theater Command of the Chinese People's Liberation Army · Shenyang, Chinano status→Not yet recruiting
  • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
  • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Xiamen University · Xiamen, Chinano status→Not yet recruiting
  • Zhongshan Hospital, Xiamen University · Xiamen, Chinano status→Not yet recruiting
  • Zibo Central Hospital · Zibo, Chinano status→Not yet recruiting
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    15 sites changed recruiting status (14 now not yet recruiting, 1 now recruiting)
    Show 15 sites
    • West China Hospital, Sichuan University · Chengdu, Chinano status→Not yet recruiting
    • The Affiliated Hospital of Guizhou Medical University · Guizhou, Chinano status→Not yet recruiting
    • Zhejiang Provincial People's Hospital · Hangzhou, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Nanchang University · Nanchang, Chinano status→Not yet recruiting
    • General Hospital of the Eastern Theater Command of the Chinese People's Liberation Army · Nanjing, Chinano status→Recruiting
    • Li Huili Hospital, Ningbo Medical Center · Ningbo, Chinano status→Not yet recruiting
    • Shanghai General Hospital · Shanghai, Chinano status→Not yet recruiting
    • General Hospital of Northern Theater Command of the Chinese People's Liberation Army · Shenyang, Chinano status→Not yet recruiting
    • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
    • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Xiamen University · Xiamen, Chinano status→Not yet recruiting
    • Zhongshan Hospital, Xiamen University · Xiamen, Chinano status→Not yet recruiting
    • Zibo Central Hospital · Zibo, Chinano status→Not yet recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07803965
Lead sponsor
Beijing Sungen Biomedical Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Sep 30, 2026
Primary completion
Nov 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Lily Shi
Contact
liping.shi@hotgen.com.cn
+86 13381070876

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGC001

Start the discussion